Browse News
Filter News
Found 78 articles
-
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
12/4/2023
Catalyst Pharmaceuticals, Inc. today announced the appointment of Michael W. Kalb as its Executive Vice President and Chief Financial Officer, effective on January 1, 2024.
-
Rapport Therapeutics Appoints Chief Financial Officer
10/30/2023
Rapport Therapeutics, Inc. today announced the appointment of industry veteran Troy Ignelzi as Chief Financial Officer, effective November 1, 2023.
-
Inotiv, Inc. Announces Changes to its Board Composition
10/16/2023
Inotiv, Inc., a leading contract research organization, announced the appointment of Terry Coelho to its Board of Directors.
-
Bexion Pharmaceuticals, Inc. Appoints Dr. Catherine Pearce, DHSc, MBA, to Board of Directors
10/10/2023
Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Dr. Catherine Pearce, DHSc, MBA, to the Company's Board of Directors, effective October 1, 2023.
-
The RNAi therapy, which the companies are co-developing and commercializing, reduced blood pressure in hypertensive patients with high cardiovascular risk by 15 mmHg over placebo.
-
Westlake Village BioPartners Launches $450 Million Fund and Appoints Next Generation of Leaders
7/17/2023
Westlake Village BioPartners announced the launch of its third fund of $450 million to incubate and grow early stage next-generation biotechnology companies in the Los Angeles region and beyond.
-
Abivax Announces the Appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors
7/11/2023
Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, announces today the appointment of June Lee, M.D. and Troy Ignelzi as new independent members of the Abivax Board of Directors.
-
9 Top M&As in the First Half of 2023
6/28/2023
Despite a challenging economic climate and gloomy forecast, 2023 has still notched some mega-deals for biopharmas. BioSpace highlights the biggest deals in the industry this year. -
Abivax Appoints Ida Hatoum as Chief People Officer
6/8/2023
Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces the appointment of Ida Hatoum as Chief People Officer.
-
Gamida Cell Appoints Terry Coelho as CFO
5/22/2023
Gamida Cell Ltd. today announced the appointment of Terry Coelho as Chief Financial Officer effective immediately.
-
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
5/12/2023
Impel Pharmaceuticals Inc. (NASDAQ: IMPL) today reported financial results for the first quarter ended March 31, 2023 and provided a business update.
-
Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer
5/10/2023
Impel Pharmaceuticals today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023.
-
Abivax Appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair
4/5/2023
Abivax SA (Euronext Paris:FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces the appointment of Marc de Garidel as Chief Executive Officer (CEO) and Interim Board Chair, effective May 5, 2023.
-
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors
3/13/2023
HOOKIPA Pharma Inc. announced today that Terry Coelho will join its Board of Directors, Audit Committee and Compensation Committee, effective April 3, 2023.
-
CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat
2/21/2023
CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) on the anticipated Phase 3 program for baxdrostat in hypertension.
-
AstraZeneca announced it is making significant cuts from its pipeline in an attempt to realign its priorities and recover from waning COVID-19 drug sales.
-
AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
1/23/2023
AstraZeneca is commencing today, through a subsidiary, a tender offer to purchase all outstanding shares of CinCor Pharma, Inc. (CinCor), for $26 per share in cash at closing, plus a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission for a baxdrostat product.
-
The pharma titan adds an intriguing blood pressure medication to its line up with a buyout of CinCor.
-
JPM Day 1: Highlights
1/9/2023
Stay on top of what's happening at JPM. BioSpace is covering all the key announcements all week. -
CinCor Pharma to be Acquired by AstraZeneca
1/9/2023
CinCor Pharma, Inc. announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor.